
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Pseudoporphyria (PP) is a photo-induced cutaneous bullous disease that resembles PCT and EPP. NSAIDs are thought to be the culprit in this condition.






